Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Nafarelin, sold under the brand name Synarel among others, is a gonadotropin-releasing hormone agonist (GnRH agonist) medication which is used in the treatment of endometriosis and early puberty. It is also used to treat uterine fibroids, to control ovarian stimulation in in vitro fertilization (IVF), and as part of transgender hormone therapy. The medication is used as a nasal spray two to three times per day.
Read the full article on WikipediaEndometriosis Clinical criteria: Treatment Phase: Initial treatment, for up to 6 months The condition must be visually proven.
Assisted Reproductive Technology Clinical criteria: The treatment must be for prevention of premature luteinisation and ovulation, AND Patient must be undergoing controlled ovarian stimulation, AND Patient must be receiving medical services as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule.
“Nafarelin is a GnRH agonist, or an agonist of the GnRH receptor, the biological target of GnRH. It works by continuously activating the GnRH receptor, which results in profound desensitization of the receptor such that it becomes non-functional. As a result, nafarelin suppresses the GnRH-induced secretion of the gonadotropins, luteinizing hormone and follicle-stimulating hormone, from the pituitary gland. This, in turn, results in profound suppression of gonadal sex hormone production, as well as reversible suppression of fertility.”
“IN: 2.5–3.0 hoursSCTooltip Subcutaneous injection: 86 hours (metabolites)”
Working under the parallel aged-care framework? Aged-care equivalent →